Valuation: Krystal Biotech, Inc.

Market Cap 10.16B 8.72B 8.14B 7.47B 14.04B 971B 14.28B 96.05B 37.61B 487B 38.16B 37.33B 1,611B P/E 2026 *
45.3x
P/E 2027 * 36.6x
Enterprise Value 10.16B 8.72B 8.14B 7.47B 14.04B 971B 14.28B 96.05B 37.61B 487B 38.16B 37.33B 1,611B EV / Sales 2026 *
19.8x
EV / Sales 2027 * 15.5x
Free-Float
89.17%
Yield 2026 *
-
Yield 2027 * -
1 day+3.16%
1 week+3.15%
Current month+0.65%
1 month-3.25%
3 months+17.06%
6 months+30.71%
Current year+39.26%
1 week 320.62
Extreme 320.62
345.56
1 month 297.02
Extreme 297.02
369
Current year 235.6
Extreme 235.605
382.54
1 year 136.73
Extreme 136.73
382.54
3 years 93.95
Extreme 93.95
382.54
5 years 38.86
Extreme 38.8563
382.54
10 years 8.03
Extreme 8.03
382.54
Manager TitleAgeSince
Chief Operating Officer 61 2016-04-14
Chief Executive Officer 61 2016-04-14
Investor Relations Contact - -
Director TitleAgeSince
Chairman 61 2016-04-14
Director/Board Member 61 2016-04-14
Director/Board Member 60 2016-10-31
Date Insider Type Main position Quantity % Market Cap.
8/14/26 Don

Director

-28,691 0.0973%
3/1/26 Other

EVP, Head of International

51,478 0.1761%
3/1/26 Other

General Counsel

68,165 0.2332%
Change 5-day change 1-year change 3-year change Capi.($)
+3.16%+3.15%+138.50%+187.55% 9.85B
+3.78%+5.37%+47.06%+3.50% 80.91B
+3.20%+24.21%-23.74%-35.56% 53.62B
+0.85%-4.04%-2.31%+30.25% 50.13B
+0.23%-1.80%+13.14%+170.56% 47.97B
+4.24%+6.08%+59.56%-15.16% 31.41B
+176.97%+173.88%+524.79%+71.60% 25.14B
+4.05%+6.38%+50.33%+100.61% 25.03B
+1.66%+2.83%+0.51%+212.40% 21.45B
+0.22%+4.68%+66.64%+127.79% 16.93B
Average +1.78%+21.32%+87.45%+85.35% 36.24B
Weighted average by Cap. +2.07%+16.43%+60.35%+56.52%

Financials

2026 *2027 *
Net sales 513M 440M 411M 377M 708M 49B 720M 4.84B 1.9B 24.57B 1.92B 1.88B 81.25B 655M 561M 524M 481M 905M 62.56B 919M 6.19B 2.42B 31.38B 2.46B 2.4B 104B
Net income 237M 204M 190M 174M 328M 22.69B 333M 2.24B 879M 11.38B 891M 872M 37.62B 307M 263M 246M 225M 424M 29.3B 431M 2.9B 1.13B 14.7B 1.15B 1.13B 48.59B
Net Debt - -
Logo Krystal Biotech, Inc.
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Employees
295
Date Price Change Volume
26-08-19 US$343.34 +3.16% 162,842
26-08-18 US$332.82 -0.87% 148,469
26-08-17 US$335.73 +1.04% 255,136
26-08-14 US$332.27 +1.20% 167,864
26-08-13 US$328.34 -1.36% 135,628
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
343.34USD
Average target price
385.00USD
Spread / Average Target
+12.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KRYS Stock